NeuroOne Added to Russell Microcap Index

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that it has been added as a member of the Russell Microcap Index, effective at the opening of the U.S. market on June 29, as part of the 2026 Russell indexes reconstitution. The addition to the index, which is widely followed by investment managers and institutional investors, could increase the company's visibility and attract additional investment from index funds.

The semi-annual June reconstitution of the Russell US Indexes captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the Russell 3000 Index, which remains in place for half a year beginning 2026, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index, as well as the appropriate growth and value style indexes. The Russell Microcap Index consists of the smallest 1,000 securities in the Russell 2000 Index, plus the next 1,000 smallest eligible securities by market cap. FTSE Russell determines membership for its indexes primarily by objective, market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2025, about $12.2 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. For more information on the Russell Microcap Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

NeuroOne is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. The company markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.

The inclusion in the Russell Microcap Index is a significant milestone for NeuroOne, as it may lead to increased liquidity and broader investor awareness. Being part of the index could also provide a stable base of shareholders, as index funds tracking the Russell Microcap Index will automatically include the stock in their portfolios.